

Francesco Mannavola

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8437142/francesco-mannavola-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

816
citations

14
h-index

24
g-index

24
ext. papers

1,068
ext. citations

5.3
avg, IF

4.35
L-index

#	Paper	IF	Citations
23	A Lipidomic Approach to Identify Potential Biomarkers in Exosomes From Melanoma Cells With Different Metastatic Potential. <i>Frontiers in Physiology</i> , 2021 , 12, 748895	4.6	1
22	The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. <i>Genes</i> , 2021 , 12,	4.2	3
21	DLC-1 down-regulation via exosomal miR-106b-3p exchange promotes CRC metastasis by the epithelial-to-mesenchymal transition. <i>Clinical Science</i> , 2020 , 134, 955-959	6.5	8
20	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020 , 10, 1652	5.3	6
19	Non-Melanoma Skin Cancers: Biological and Clinical Features. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	28
18	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 581130	5.3	4
17	Large Extracellular Vesicles-A New Frontier of Liquid Biopsy in Oncology. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
16	Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920905415	5.4	6
15	The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine. <i>Tumor Biology</i> , 2019 , 42, 1010428319837138	2.9	18
14	Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis. <i>Journal of Translational Medicine</i> , 2019 , 17, 230	8.5	29
13	Revisiting the Role of Exosomes in Colorectal Cancer:. <i>Frontiers in Oncology</i> , 2019 , 9, 521	5.3	24
12	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919875549	5.4	10
11	Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2019 , 21,	6.3	22
10	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. <i>Frontiers in Oncology</i> , 2019 , 9, 1148	5.3	52
9	Gene Fusion in NSCLC 2019 , 443-464		
8	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. <i>Oncolimmunology</i> , 2018 , 7, e1387706	7.2	56
7	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. <i>Oncotarget</i> , 2018 , 9, 20826-20837	3.3	74

6	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918794630	5.4	202
5	pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo. <i>Stem Cell Research and Therapy</i> , 2017 , 8, 206	8.3	16
4	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. <i>Oncotarget</i> , 2017 , 8, 106132-106142	3.3	109
3	miRNAs in melanoma: a defined role in tumor progression and metastasis. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 79-89	5.1	35
2	Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker. <i>Journal of Translational Medicine</i> , 2015 , 13, P14	8.5	78
1	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015 , 6, 31604-12	3.3	27